Adc Therapeutics (ADCT)

Trade ADCT now with
6/10/2022 3:31:35 AM ADC Therapeutics Reports Results From Pivotal Phase 2 Clinical Trial Of Cami In Relapsed Or Refractory Hodgkin Lymphoma
5/9/2022 7:11:37 AM ADC Therapeutics Q1 Net Loss $16.7 Mln Or $0.22/Shr Vs Loss Of $51.5 Mln Or $0.67/Shr Last Year
5/9/2022 7:10:58 AM ADC Therapeutics' Chris Martin Steps Down As CEO
4/4/2022 7:22:00 AM ADC Therapeutics Gets Permanent J-Code For ZYNLONTA From U.S. Centers For Medicare & Medicaid Services
3/3/2022 7:09:44 AM ADC Therapeutics SA Q4 Net Loss $34.4 Mln Vs Net Loss $230 Mln Last Year
1/18/2022 5:13:38 AM ADC Therapeutics Unveils Exclusive License With Mitsubishi Tanabe Pharma To Develop ZYNLONTA In Japan
11/2/2021 7:12:06 AM ADC Therapeutics SA Q3 Loss/shr $0.93 Vs. Loss/shr $0.29 Last Year
10/29/2021 7:19:45 AM ADC Therapeutics Announces Validation Of MAA By European Medicines Agency For ZYNLONTA For Relapsed Or Refractory DLBCL
9/27/2021 7:19:26 AM ADC Therapeutics Doses First Patient In Phase 1 Clinical Trial Of ADCT-901 In Advanced Solid Tumors
9/13/2021 7:18:13 AM ADC Therapeutics Gets Orphan Drug Designation In Europe For ZYNLONTA(r)
9/3/2021 7:28:00 AM ADC Therapeutics: SVP And Chief Medical Officer Jay Feingold To Depart To Pursue A New Opportunity
8/26/2021 7:19:11 AM ADC Therapeutics Enters Royalty Purchase Agreement With HealthCare Royalty Partners For Up To $325 Mln
8/3/2021 7:17:51 AM ADC Therapeutics Q2 Net Loss $72.6 Mln Or $0.95/shr Vs. Loss $126.6 Mln Or $2.01/shr Prior Year
6/22/2021 10:04:25 AM ADC Announces Interim Results From Pivotal Phase 2 Trial Of Camidanlumab Tesirine Presented
6/18/2021 7:27:16 AM ADC Therapeutics Presents Updated ZYNLONTA Clinical Data At Annual International Conference On Malignant Lymphoma
6/11/2021 7:18:49 AM ADC Therapeutics Shareholders Approve All Resolutions At Annual General Meeting
5/17/2021 7:18:22 AM ADC Therapeutics Announces Receipt Of $50 Mln Second Tranche Of Convertible Credit Facility With Deerfield
5/12/2021 7:20:28 AM ADC Therapeutics Announces Online Publication Of LOTIS-2 Results In The Lancet Oncology